{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "12802751",
  "DateCompleted": {
    "Year": "2003",
    "Month": "07",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "12",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2003",
        "Month": "06",
        "Day": "06"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1537-6591",
      "JournalIssue": {
        "Volume": "36",
        "Issue": "12",
        "PubDate": {
          "Year": "2003",
          "Month": "Jun",
          "Day": "15"
        }
      },
      "Title": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",
      "ISOAbbreviation": "Clin Infect Dis"
    },
    "ArticleTitle": "Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.",
    "Pagination": {
      "StartPage": "1523",
      "EndPage": "1532",
      "MedlinePgn": "1523-32"
    },
    "Abstract": {
      "AbstractText": [
        "The novel capsid-binding antiviral pleconaril inhibits in vitro replication of most rhinoviruses and enteroviruses. Oral pleconaril treatment was studied in 2 parallel randomized, double-blind, placebo-controlled trials. Among 1363 picornavirus-infected participants (65%) in the studies combined, the median time to alleviation of illness was 1 day shorter for pleconaril recipients than for placebo recipients (P<.001). Cold symptom scores and frequency of picornavirus cultured from nasal mucus specimens were lower among pleconaril recipients by day 2 of treatment. No treatment effects were seen in those without picornavirus infection. Pleconaril was associated with a higher incidence of nausea (6% vs. 4%) and diarrhea (9% vs. 7%) and with small increases in mean serum cholesterol levels and platelet counts, compared with baseline measurements. A subsequent 6-week prophylaxis study found that pleconaril induces cytochrome P-450 3A enzymes, which metabolize a variety of drugs, including ethinyl estradiol. Early pleconaril treatment was well tolerated and significantly reduced the duration and severity of colds due to picornaviruses in adults."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Internal Medicine, University of Virginia, Charlottesville, USA. FGH@virginia.edu"
          }
        ],
        "LastName": "Hayden",
        "ForeName": "Frederick G",
        "Initials": "FG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Herrington",
        "ForeName": "Darrell T",
        "Initials": "DT"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Coats",
        "ForeName": "Teresa L",
        "Initials": "TL"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kim",
        "ForeName": "Kenneth",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Cooper",
        "ForeName": "Ellen C",
        "Initials": "EC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Villano",
        "ForeName": "Stephen A",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Liu",
        "ForeName": "Siyu",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hudson",
        "ForeName": "Spencer",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pevear",
        "ForeName": "Daniel C",
        "Initials": "DC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Collett",
        "ForeName": "Marc",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "McKinlay",
        "ForeName": "Mark",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "CollectiveName": "Pleconaril Respiratory Infection Study Group"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article",
      "Multicenter Study",
      "Randomized Controlled Trial",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Clin Infect Dis",
    "NlmUniqueID": "9203213",
    "ISSNLinking": "1058-4838"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oxadiazoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oxazoles"
    },
    {
      "RegistryNumber": "9H4570Q89D",
      "NameOfSubstance": "pleconaril"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "Clin Infect Dis. 2003 Dec 15;37(12):1722",
      "PMID": "14689362"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Oral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [
        "chemically induced"
      ],
      "DescriptorName": "Diarrhea"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "chemically induced"
      ],
      "DescriptorName": "Nausea"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Oxadiazoles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Oxazoles"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Picornaviridae"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Picornaviridae Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}